ECSP17035416A - Una nueva forma cristalina de un derivado de bencimidazol y un método de preparación de los mismos - Google Patents

Una nueva forma cristalina de un derivado de bencimidazol y un método de preparación de los mismos

Info

Publication number
ECSP17035416A
ECSP17035416A ECIEPI201735416A ECPI201735416A ECSP17035416A EC SP17035416 A ECSP17035416 A EC SP17035416A EC IEPI201735416 A ECIEPI201735416 A EC IEPI201735416A EC PI201735416 A ECPI201735416 A EC PI201735416A EC SP17035416 A ECSP17035416 A EC SP17035416A
Authority
EC
Ecuador
Prior art keywords
crystalline form
new crystalline
preparing
benzimidazole derivative
long
Prior art date
Application number
ECIEPI201735416A
Other languages
English (en)
Inventor
Brands Llc Prometheus
Eun Sun Kim
For Children Inc Highlights
Young Ju Kim
Seung Pyeong Heo
Mahmoudi Hamed
Company Llc Cambria
Inc Zaner-Bloser
Ji Yun Lee
Original Assignee
Cj Healthcare Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56417901&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP17035416(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cj Healthcare Corp filed Critical Cj Healthcare Corp
Publication of ECSP17035416A publication Critical patent/ECSP17035416A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La presente invención se refiere a una nueva forma cristalina de un derivado de bencimidazol y un procedimiento de preparación de estos. La nueva forma cristalina de acuerdo con la presente invención apenas cambia de forma química y/o física en un estado de foto-estrés de largo plazo, tiene higroscopicidad baja y tiene una capacidad inductora de electricidad estática extremadamente baja, de este modo es ventajosa para la formulación, y debido a la excelente estabilidad de la forma de cristal misma, es muy útil para el almacenamiento a largo plazo del compuesto.
ECIEPI201735416A 2015-01-20 2017-06-07 Una nueva forma cristalina de un derivado de bencimidazol y un método de preparación de los mismos ECSP17035416A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020150009326A KR101684053B1 (ko) 2015-01-20 2015-01-20 벤즈이미다졸 유도체의 신규 결정형 및 이의 제조방법

Publications (1)

Publication Number Publication Date
ECSP17035416A true ECSP17035416A (es) 2017-11-30

Family

ID=56417901

Family Applications (1)

Application Number Title Priority Date Filing Date
ECIEPI201735416A ECSP17035416A (es) 2015-01-20 2017-06-07 Una nueva forma cristalina de un derivado de bencimidazol y un método de preparación de los mismos

Country Status (32)

Country Link
US (1) US9908870B2 (es)
EP (1) EP3248967B1 (es)
JP (2) JP6535748B2 (es)
KR (1) KR101684053B1 (es)
CN (2) CN107207478B (es)
AR (1) AR103444A1 (es)
BR (1) BR102016001167B1 (es)
CL (1) CL2017001377A1 (es)
CO (1) CO2017005396A2 (es)
CY (1) CY1123423T1 (es)
DK (1) DK3248967T3 (es)
EA (1) EA030919B1 (es)
EC (1) ECSP17035416A (es)
ES (1) ES2816646T3 (es)
GE (1) GEP20196974B (es)
HR (1) HRP20201275T1 (es)
HU (1) HUE050979T2 (es)
IL (1) IL253186B (es)
JO (1) JO3592B1 (es)
LT (1) LT3248967T (es)
MX (1) MX359916B (es)
MY (1) MY186830A (es)
PH (2) PH12016000029B1 (es)
PL (1) PL3248967T3 (es)
PT (1) PT3248967T (es)
RS (1) RS60758B1 (es)
SA (1) SA517381904B1 (es)
SG (1) SG10201509488YA (es)
SI (1) SI3248967T1 (es)
TW (1) TWI589575B (es)
UY (1) UY36521A (es)
WO (1) WO2016117814A2 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101829706B1 (ko) * 2016-09-21 2018-02-19 씨제이헬스케어 주식회사 벤즈이미다졸 유도체의 산부가염
KR20230114163A (ko) 2022-01-24 2023-08-01 엠에프씨 주식회사 칼륨 경쟁적 위산분비억제제 계열 약물의 신규한 무정형 고체분산체 및 그의 제조방법
KR20230114164A (ko) 2022-01-24 2023-08-01 엠에프씨 주식회사 벤즈이미다졸 유도체의 공동 무정형 고형체, 이의 제조방법 및 이를 포함하는 약제학적 조성물
KR20240028127A (ko) 2022-08-24 2024-03-05 위더스제약주식회사 테고프라잔 고체분산체 조성물
WO2024045255A1 (zh) * 2022-08-30 2024-03-07 上海皓元医药股份有限公司 一种特戈拉赞晶型b及其制备方法
KR20240109898A (ko) 2023-01-05 2024-07-12 위더스제약주식회사 무정형 테고프라잔 고체분산체
KR20240120271A (ko) 2023-01-31 2024-08-07 주식회사 엔비피헬스케어 신규한 테고프라잔 말론산 공무정형
WO2024171128A1 (en) * 2023-02-18 2024-08-22 Lee Pharma Limited Stable amorphous form of potassium-competitive acid blocker and process for the preparation thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR043063A1 (es) * 2002-12-13 2005-07-13 Altana Pharma Ag Bencimidazoles 6-sustituidos y su uso como inhibidores de secreciones gastricas
US7256294B2 (en) * 2005-05-25 2007-08-14 Theravance, Inc. Crystalline form of a benzimidazole-carboxamide medicinal compound
EP1893197B1 (en) * 2005-06-14 2009-09-09 RaQualia Pharma Inc Chromane substituted benzimidazole derivatives as acid pump antagonists
JP4481344B2 (ja) * 2005-12-19 2010-06-16 ラクオリア創薬株式会社 クロマン置換ベンゾイミダゾール誘導体及び酸ポンプ阻害剤としてのそれらの使用
PT2586782E (pt) * 2008-07-03 2015-02-03 Ratiopharm Gmbh Sais cristalinos de sitagliptina
CN105919998B (zh) * 2009-07-09 2021-08-24 拉夸里亚创药株式会社 用于治疗与异常肠胃运动有关的疾病的酸泵拮抗剂
JP2014047304A (ja) * 2012-08-31 2014-03-17 Sanyo Chem Ind Ltd 樹脂粒子の製造方法
GB2508352B (en) * 2012-11-28 2017-08-16 Douwe Egberts Bv Treating soluble coffee
CN104995188B (zh) * 2013-01-11 2018-09-14 诺华股份有限公司 2-((1r,4r)-4-(4-(5-(苯并噁唑-2-基氨基)吡啶-2-基)苯基)环己基)乙酸的葡甲胺盐形式和它们作为dgat1抑制剂的用途
EA033632B1 (ru) * 2014-12-19 2019-11-12 Glaxosmithkline Ip Dev Ltd 3-(6-АЛКОКСИ-5-ХЛОРБЕНЗО[d]ИЗОКСАЗОЛ-3-ИЛ)ПРОПИОНОВАЯ КИСЛОТА, ПОЛЕЗНАЯ В КАЧЕСТВЕ ИНГИБИТОРОВ КИНУРЕНИНМОНООКСИГЕНАЗЫ

Also Published As

Publication number Publication date
US9908870B2 (en) 2018-03-06
LT3248967T (lt) 2020-10-12
KR20160089928A (ko) 2016-07-29
KR101684053B1 (ko) 2016-12-08
JP6535748B2 (ja) 2019-06-26
EA030919B1 (ru) 2018-10-31
CN111187259B (zh) 2023-10-13
BR102016001167A2 (pt) 2018-03-20
ES2816646T3 (es) 2021-04-05
TWI589575B (zh) 2017-07-01
HRP20201275T1 (hr) 2020-11-13
JP2019104760A (ja) 2019-06-27
PH12016000029A1 (en) 2017-07-24
PL3248967T3 (pl) 2020-12-28
CN111187259A (zh) 2020-05-22
RS60758B1 (sr) 2020-10-30
GEP20196974B (en) 2019-06-10
HUE050979T2 (hu) 2021-01-28
MY186830A (en) 2021-08-24
US20180009791A1 (en) 2018-01-11
IL253186B (en) 2020-11-30
PT3248967T (pt) 2020-09-11
CY1123423T1 (el) 2021-12-31
SI3248967T1 (sl) 2020-11-30
DK3248967T3 (da) 2020-09-07
EA201791151A1 (ru) 2017-12-29
WO2016117814A2 (ko) 2016-07-28
EP3248967B1 (en) 2020-06-24
CO2017005396A2 (es) 2017-07-11
AR103444A1 (es) 2017-05-10
MX359916B (es) 2018-10-15
TW201627305A (zh) 2016-08-01
WO2016117814A3 (ko) 2016-10-06
PH12019000462A1 (en) 2020-10-12
BR102016001167B1 (pt) 2023-03-07
CN107207478A (zh) 2017-09-26
JO3592B1 (ar) 2020-07-05
UY36521A (es) 2016-08-31
SA517381904B1 (ar) 2020-12-07
PH12016000029B1 (en) 2017-07-24
EP3248967A4 (en) 2018-10-03
SG10201509488YA (en) 2016-08-30
JP2018502140A (ja) 2018-01-25
CL2017001377A1 (es) 2017-12-15
CN107207478B (zh) 2020-09-01
EP3248967A2 (en) 2017-11-29
IL253186A (en) 2018-04-30
MX2016000751A (es) 2016-08-11

Similar Documents

Publication Publication Date Title
ECSP17035416A (es) Una nueva forma cristalina de un derivado de bencimidazol y un método de preparación de los mismos
DOP2017000267A (es) Amidas heterocíclicas como inhibidores de quinasa
CO2017012268A2 (es) Derivados de sulfamoilarilamida ciclados y su uso como medicamentos para el tratamiento de la hepatitis b
CO2017003833A2 (es) Pirimidinonas como inhibidores del factor xia
CL2018003323A1 (es) Piridinas sustituidas con heteroarilo y métodos de uso.
CU24411B1 (es) Compuesto derivado de benzamida sustituida con 1,3-tiazol-2-ilo útil para el tratamiento de trastornos neurogénicos
CO2017001152A2 (es) Espirocicloheptanos como inhibidores de la cinasa rho (rock)
GT201600010A (es) Derivaods de pirrolamida sustituidos con glioxamida y su uso como medicamentos para el tratamiento de la hepatitis b
NI201500161A (es) Derivados de sulfamoilpirrolamida y su uso como medicamentos para el tratamiento de la hepatitis b
CU24419B1 (es) 2-(morfolin-4-il)-1,7-naftiridinas útiles en el tratamiento o la profilaxis de enfermedades hiperproliferativas
UY35971A (es) Macrociclos con grupos p2? aromáticos como inhibidores del factor xia
AR106192A1 (es) Formas cristalinas de un agente antiviral contra la hepatitis b
UY35617A (es) Inhibidores de la fosfatidilinositol 3-quinasa
DOP2017000278A (es) Piridinas sustituidas y método de uso
UY35630A (es) Carboxamidas primarias como inhibidores de btk
CU24410B1 (es) Benzimidazol-2-aminas como inhibidores de midh1
CO2017002253A2 (es) Compuesto dirigido a il-23a y tnf-alfa
BR112018002461A2 (pt) compostos para dispositivos opticamente ativos
AR102981A1 (es) Inhibidores de la necrosis celular y métodos de preparación de los mismos
PE20161368A1 (es) Inhibidores de diacilglicerol aciltranferasa 2
CR20150604A (es) Proceso para la preparación de eritrocitos cargados con una o más sustancias de interés farmacéutico y eritrocitos así obtenidos
GT201600091A (es) Derivados de purina 2, 6-sustituidos y su uso en el tratamiento de trastornos proliferativos
CR20160224A (es) Composición herbicida que comprende inhibidores ACC
CR20180298A (es) Nuevos derivados de fenilo
UY36800A (es) Hidrazidas de ácido carboxílico arilo y heteroarilo sustituidas o sus sales y su uso para aumentar la tolerancia al estrés en plantas